StockData
InMed Pharmaceuticals Inc. logo

InMed Pharmaceuticals Inc. (MTRI) stock

MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/30
$17.50−2.37 (-11.93%)

Close on Nov 17, 2026Market cap $96.14MP/E –Yield –

InMed Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

InMed Pharmaceuticals's revenue for the twelve months ending Dec 31, 2025 was $4.51M, down 6.7% year over year. For fiscal 2025 it was $4.94M, up 7.5% from the year before. The highest annual figure on record is $4.94M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Jun 30, 2025$4.94M+7.5%
FY2024Jun 30, 2024$4.60M+11.2%
FY2023Jun 30, 2023$4.14M+279.6%
FY2022Jun 30, 2022$1.09M-42.8%
FY2021Jun 30, 2021$1.90M–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ4 2025Dec 31, 2025$820.19K-26.2%
Q1 FY2026CQ3 2025Sep 30, 2025$1.12M-11.4%
Q4 FY2025CQ2 2025Jun 30, 2025$1.30M+1.7%
Q3 FY2025CQ1 2025Mar 31, 2025$1.26M+7.6%
Q2 FY2025CQ4 2024Dec 31, 2024$1.11M-10.4%
Q1 FY2025CQ3 2024Sep 30, 2024$1.26M+40.2%
Q4 FY2024CQ2 2024Jun 30, 2024$1.28M-44.5%
Q3 FY2024CQ1 2024Mar 31, 2024$1.17M+13.4%
Q2 FY2024CQ4 2023Dec 31, 2023$1.24M+164.0%
Q1 FY2024CQ3 2023Sep 30, 2023$901.86K+181.1%
Q4 FY2023CQ2 2023Jun 30, 2023$2.31M+349.0%
Q3 FY2023CQ1 2023Mar 31, 2023$1.03M+234.0%
Q2 FY2023CQ4 2022Dec 31, 2022$469.78K+77.2%
Q1 FY2023CQ3 2022Sep 30, 2022$320.79K-63.6%
Q4 FY2022CQ2 2022Jun 30, 2022$514.76K+17.7%
Q3 FY2022CQ1 2022Mar 31, 2022$309.59K+11.8%
Q2 FY2022CQ4 2021Dec 31, 2021$265.09K–
Q4 FY2021CQ2 2021Jun 30, 2021$880.63K–
Q3 FY2021CQ1 2021Mar 31, 2021$437.31K–
Q2 FY2021CQ4 2020Dec 31, 2020$276.79K–

More InMed Pharmaceuticals figures

See a number that looks wrong?